ArticleThe Journal of infection2022

The efficacy and safety of IBI314 on delta and omicron variant of SARS-CoV-2: First-in-human evidence.

Ling Sang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.